Ianalumab
Published
Unassigned
New Medicines
Autoimmune hepatitis (AIH) in adults
Information
New molecular entity
Novartis
Novartis
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Human IgG1/κ monoclonal antibody that targets human B cell activating factor (BAFF) receptor, predominantly expressed on human B cells. Ianalumab competitively inhibits binding of BAFF to BAFF receptors and blocks BAFF receptor-mediated signalling.
Autoimmune hepatitis is a chronic and usually lifelong condition where the immune system attacks the liver. It is estimated to affect between 10 and 17 people per 100,000 in Europe [1].
Autoimmune hepatitis (AIH) in adults
Subcutaneous injection